AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. is a manufacturer and supplier of Freeze-Dried Rabies Vaccine Vero Cell for Human Use. We support bulk purchasing and cross-border supply of products to provide safe and effective vaccine products to customers worldwide.

What is a Rabies Vaccine?

A rabies vaccine is a biological product used to prevent rabies virus infection. It stimulates the body to produce specific antibodies that neutralize the invading rabies virus, reducing the risk of illness (the fatality rate of rabies is almost 100%, and vaccination is the key preventive measure).

Usage History

The rabies vaccine was invented by the French scientist Louis Pasteur in 1885. It was first used on Joseph Meister, a 9-year-old boy bitten by a rabid dog, successfully saving the lucky child's life—this is the earliest recorded use of the rabies vaccine in human history.

In the mid-20th century, inactivated rabies vaccines were developed, addressing the safety issues of attenuated live vaccines and becoming the mainstream for human use.

In the 1980s, with the rise of genetic engineering technology, recombinant rabies vaccines entered the research and development phase, and were gradually marketed in the 1990s, further improving safety and immunogenicity.

To date, inactivated vaccines remain the global mainstream for human use, while genetically engineered vaccines are rapidly gaining popularity due to their advantages. The "five-dose schedule" and "2-1-1 schedule" have become standardized vaccination procedures for post-exposure prophylaxis.

Classification (by Technical Route)

Inactivated Vaccine: The mainstream type, made from inactivated rabies virus strains. It features high safety and stable immunogenicity, suitable for both humans and animals.

Attenuated Live Vaccine: Produced by weakening the virulence of the rabies virus. It has strong immunogenicity but slightly lower safety than inactivated vaccines, and is mostly used for animal immunization (rarely for human use in some regions).

Genetically Engineered Vaccine: Expresses viral antigens (such as glycoprotein G) through genetic recombination technology. It has high purity, mild side effects, and is a development direction in recent years (e.g., CHO cell-expressed vaccines).

Key Differences Between Different Types of Rabies Vaccines

Common Questions and Solutions

Is it still useful to get vaccinated more than 24 hours after being bitten by a dog?

Yes! As long as no symptoms occur, get vaccinated as soon as possible. For severe exposure, rabies immunoglobulin (RIG) should be injected simultaneously—do not give up vaccination due to delayed timing.

Is it normal to experience redness, swelling, or low-grade fever after vaccination?

These are normal local/systemic reactions (incidence rate: approximately 10%-20%), which usually subside on their own within 1-2 days without special treatment. Seek medical attention immediately for high fever or allergies.

Can pregnant or lactating women be vaccinated?

Yes! Rabies vaccines (inactivated or genetically engineered) have no adverse effects on fetuses or infants. Prioritize vaccination in case of exposure.

Can rabies occur after completing the vaccination?

It is extremely rare (e.g., virus latency before vaccination, severe exposure without RIG). The protection rate exceeds 99% after standardized vaccination.

If a pet has been vaccinated, do I still need to get vaccinated if scratched by it?

Yes! The protection rate of animal vaccines is not 100%, and virus carriage cannot be completely ruled out. Follow the post-exposure vaccination procedure.

If you have any further needs or inquiries, please feel free to contact us via international@aimbio.com

AIM Honesty Biopharmaceutical Co., Ltd., which owns the RECVAX® brand, is a Recombinant Hepatitis B Vaccine Hansenula Polymorpha manufacturer from China. We use advanced technology to provide safe and reliable vaccine products for people of all ages, effectively protecting against hepatitis.

What is Hepatitis B?

Hepatitis B is a viral liver disease. Without prevention, approximately 5% to 10% of infected individuals will develop chronic liver disease, increasing their lifelong risk of cirrhosis or liver cancer. It is a very threatening disease. Hepatitis B vaccination has few side effects and effectively protects recipients, so timely vaccination is recommended.

Liver Cancer Prevention

Hepatitis B vaccination is a primary preventive measure for the etiology of liver cancer!

Chronic HBV infection is the most important cause of liver cancer in our country, with about 85% of liver cancer patients carrying HBV. According to WHO, in 2019 there were approximately 296 million people worldwide with chronic HBV infection, and about 820,000 people died from liver failure, cirrhosis, or primary liver cancer caused by HBV infection.

The "Expert Consensus on Primary Prevention of Liver Cancer in China" in 2018 pointed out that after excluding factors such as age and gender, compared with those who are both HBsAg and HBeAg negative, the relative risk of liver cancer for those who are HBsAg positive is 9.6, and for those who are both HBsAg and HBeAg positive, the relative risk is 60.

Immunization is the most economical and effective means to control and even eradicate infectious diseases!

Our Product

Subsidiary of AIM Vaccine, AIM Honesty Biopharmaceutical Co., Ltd. independently developed RECVAX® Recombinant Hepatitis B Vaccine (Hansenula Polymorpha).

Due to the adoption of the first domestic and internationally leading recombinant Hansenula Polymorpha expression technology platform and patented adjuvant technology, it has achieved excellent immune effects, even surpassing the same dose of imported products and even the domestic multiple-dose products.

Product Introduction

AIM Honesty RECVAX®

[Composition and Description]

This product is prepared by purifying hepatitis B virus surface antigen (HBsAg) expressed by recombinant Hansenula Polymorpha yeast and adding aluminum adjuvant. It is a milky white suspension that can be layered due to precipitation and easily shaken and dispersed.

Active ingredient: hepatitis B virus surface antigen.

Excipients: aluminum hydroxide, sodium chloride.

[Vaccinated subjects]

This vaccine is indicated for hepatitis B susceptible individuals, especially those who: (1) Newborns, especially mothers, are HBsAg and HBeAg positive. (2) Medical staff engaged in medical work and laboratory personnel exposed to blood.

[Actions and Usage]

Vaccination stimulates immunity against the hepatitis B virus. Used for prevention of hepatitis B.

[Regulation]

0.5 ml per vial (vial), 0.5 ml per human dose, containing 10μg or 20ug  HBsAg.

[Immunization procedures and doses]

(1) was injected intramuscularly into the deltoid muscle of the upper arm.

(2) The immunization schedule is three doses, administered at 0, 1, and 6 months, and newborns receive the first dose of vaccine within 24 hours of birth, one dose each time.

[Adverse reactions]

Common adverse reactions: Pain and tenderness may be felt at the injection site within 24 hours after vaccination and disappear spontaneously within 2 to 3 days in most cases.

Rare adverse reactions:

(1) Transient febrile reactions may occur in vaccinees within 72 hours after vaccination and generally persist for 1 to 2 days and resolve spontaneously.

(2) Mild to moderate redness, swelling and pain at the inoculation site. Generally, it lasts for 1 to 2 days and resolves spontaneously without treatment.

Very rare adverse reactions:

(1) Induration may occur at the inoculation site and is generally absorbed spontaneously in 1 to 2 months.

(2) Local aseptic suppuration: Pus is generally repeatedly aspirated with a syringe, and in severe cases (ulceration) it is necessary to expand the wound to remove necrotic tissue, which lasts longer and can finally be absorbed and healed.

(3) Allergic reactions: allergic rash, Arthur reaction. Arthur reaction generally appears about 10 days after inoculation, local redness and swelling lasts for a long time, and solid alcohols can be used for systemic and local treatment.

(4) Anaphylactic shock: It generally occurs within 1 hour after injection of the vaccine and should be treated with timely injection of epinephrine and other rescue measures.

[Do not avoid]

(1) Known hypersensitivity to any component of the vaccine, including excipients, formaldehyde, and yeast.

(2) Patients suffering from acute diseases, severe chronic diseases, acute attacks of chronic diseases and fever;

(3) Pregnant women.

(4) For uncontrolled epilepsy and other progressive neurological diseases;

[Precautions]

(1) Use with caution in patients with the following conditions: family and individual history of convulsion, chronic diseases, history of epilepsy, and allergic constitution.

(2) It should be shaken well when used, and should not be used if there are clots that do not disperse, foreign bodies, cracks in the vaccine bottle, or unclear labels.

(3) Vaccine bottles should be used immediately when opened.

(4) Drugs such as epinephrine should be available for emergency use in case of occasional severe allergic reactions. Those receiving the injection should be observed in the field for at least 30 minutes after the injection.

(5) If abnormal conditions such as high fever and convulsion occur after the first injection, the second injection is generally no longer injected, and for infants with maternal and fetal blocking, the second and third injections should be followed by the doctor 's advice.

(6) Freezing is strictly prohibited.

[Package and Storage]

Store and transport at 2-8℃, protected from light.

Package Container: The inner packing materials are vials, ampoules and prefilled syringes, vials: 0.5 ml × 1 vials/box, 0.5 ml × 3 vials/box, 0.5 ml × 30 vials/box; ampoules: 0.5 ml × 3 vials/box, 0.5 ml × 9 vials/box; prefilled syringes: 0.5ml × 1 vial/box.

Effective period: Vials: 36 months, ampoules: 24 months, prefilled syringes: 36 months.

Product Specification

Compared to other technical routes, RECVAX® were produced with a more rigorous pharmacopeia standard, which improve the quality and safety of the product.

Characteristic Comparison

Product Application

RECVAX® patented adjuvant technology, through in situ adsorption technology, creates an "antigen bank" in the body after the product enters, steadily releasing antigens, extending the duration of antigen action, playing a role in enhancing the stimulation of the immune response, and improving immunogenicity.

The RECVAX® series Hepatitis B Vaccine Hansenula Polymorpha has been on the market for 20 years, covering 31 provinces, cities, and autonomous regions in the country, with a total market usage of nearly 500 million doses, providing immunization plans for nearly 80% of the country's newborns.

A study led by Academician Li Lanjuan evaluated booster immunization in 5- to 15-year-old children with four different hepatitis B vaccines. After a 0-1-6-month booster series with 10 μg RECVAX® (Hansenula-yeast) vaccine, the anti-HBs seropositive rates at 1, 5, and 8 years post-booster reached 83.4 %—the highest among all four vaccines evaluated.

Professional and modern production workshops are the cornerstone of high-quality products!

AIM Vaccine is a professional Hepatitis A Inactivated Vaccine Diploid Cell manufacturer and supplier in China, we apply advanced technology; during the years, we continuously expand our pipeline of products, as we have strong production and innovation abilities.

What is Hepatitis A vaccine?

The hepatitis A vaccine is an inactivated viral vaccine that stimulates the body to produce protective antibodies against the hepatitis A virus (HAV), preventing infection and the development of hepatitis A.

It is typically administered as a 2-dose series (initial dose + a booster 6–12 months later) for long-term immunity, and is recommended for children, travelers to high-risk regions, and individuals with increased exposure risk to HAV.

Why do we need vaccines specifically for hepatitis A?

Hepatitis A vaccines are essential because the hepatitis A virus (HAV) causes acute liver infection with potentially severe symptoms (jaundice, liver damage, even fulminant hepatitis in high-risk groups), and it spreads easily via fecal-oral route (contaminated food/water, close contact) with no specific cure for the infection.

Vaccination is the most effective way to build long-term active immunity against HAV, preventing infection, stopping the virus from spreading in communities, and eliminating the risk of life-threatening liver complications—especially for children, the elderly, and people with pre-existing liver disease who are more vulnerable to severe HAV outcomes.

What’s differences between Inactivated hepatitis A vaccine and Live attenuated hepatitis A vaccine?

Elaborate on the advantages of the hepatitis A vaccine produced by AIM Action

The human diploid hepatitis A vaccine produced by AIM Action Biopharmaceutical Co., Ltd. — the inactivated hepatitis A vaccine (human diploid cells) — uses the internationally recognized safe human diploid cells (KMB17) as the culture medium, eliminating the potential viral contamination and tumorigenic risks associated with animal-derived cells. It represents an advanced and next-generation vaccine production technology that is purer and safer.

Core Features: Human-derived Cell-based Safety Assurance

1. Purity, Eliminating Animal Origin Risks: Manufactured from human diploid cells, this vaccine completely avoids potential unknown pathogens or xenogeneic proteins introduced by animal cells such as chicken embryos or hamster kidneys, ensuring purity from the source.

2. Safety record excellence: Human diploid cell matrix has been safely used worldwide for decades, widely used in high-end vaccines such as rabies, chickenpox, etc., and its safety has been clinically validated over a long period of time.

3. The immune response is more natural: The virus is cultured in human cells, and its antigen structure is closer to the shape recognized by the body during natural infection, which may induce a more balanced and lasting immune protection.

4. Wider applicability: With its high safety profile, it provides a vaccination option for a wider range of people, including those with immunocompromised status, without the concern of animal-derived allergies.

AIM Action’s hepatitis A inactivated vaccine, was listed on June 1, 2003, is one of the first inactivated vaccine manufacture to occupy the market in China.

After more than 20 years, AIM Action HAV has been tested and made a positive contribution to the elimination of viral hepatitis in China.

This vaccine offers precise dosing for both adults (over 15 years old) and children (1-15 years old including 15 years old). After completing two full doses, it induces long-term or even lifelong protective antibodies, effectively blocking viral transmission.

Hepatitis A Vaccine for Children

Engineered for children's delicate constitution and rapidly developing immune systems, the inactivated hepatitis A vaccine (human diploid cell) produced by AIM Action Biopharmaceutical Co., Ltd.（The wholly-owned subsidiary of AIM Vaccine Co., Ltd.）delivers a 0.5ml pediatric-specific dose (containing 320EU of hepatitis A virus antigen), achieving optimal balance between safety and immune efficacy. Utilizing internationally certified human diploid cell culture and inactivation technology, it provides long-lasting protection for children of 1-15 years old (including 15 years old).

[Drug Name]

Generic name: Hepatitis A Vaccine (Human Diploid Cell), Inactivated

[Components and Description]

The inactivated hepatitis A vaccine is a preparation made from hepatitis A virus (HAV) LV8 strain grown in human diploid cell KMB17 strain. After cultivation and harvest, the virus suspension Is purified and inactivated. A quantity of aluminum adjuvant is added to make the vaccine. It is a slightly milky-white suspension. Stratified precipitate may form which can be dispersed by shaking.

Active constituent: Inactivated hepatitis A virus.

Excipients: Aluminum hydroxide, 2-phenoxyethanol, glycine,sodium hydrogen sulfite, sodium hydroxide, and phosphate buffered saline (PBS).

[Eligibles]

Hepatitis A-susceptible individuals aged 1-15 years old (including 15 years old).

[Action and Use]

The product can induce immunity against hepatitis A virus in recipients following immunization. It is used to prevent hepatitis A.

[Strength]

0.5ml per vial or syringe, 0.5ml per single human dose for children, containing 320EU of hepatitis A virus antigen.

[Administration and Dosage]

(1) Shake well before use. Inject single human dose im.at deltoid insertion area of the lateral upper arm.

(2) Eligibles of 1-15 years old (including 15 years old) should be administered the pediatric dose, A single dose of vaccine is used for primary immunization, and 1 dose of vaccine for booster immunization at 6 months interval. Each dose is 0.5 ml.

[Storage]

Store and ship the product at 2-8℃, protected from light.

[Packaging]

This product is packaged in a pre-filled syringe or vial , with 1 vial or syringe per small box.

[Validity Period]

36 months.

Hepatitis A Vaccine for Adult

The AIM Action Adult Hepatitis A Vaccine is a preventive product specifically optimized for the immune system characteristics of individuals over 15 years old. Unlike pediatric formulations, this product contains 640EU of hepatitis A virus antigen per 1.0ml. This clinically validated dosage effectively stimulates the adult body to produce sufficient and long-lasting protective antibodies. Adults face relatively higher exposure risks due to work stress, frequent social interactions, and increased travel. With a focus on "strong protection and convenient administration," the vaccine provides a reliable "liver insurance" through a two-dose regimen (0 and 6 months), seamlessly integrating health protection into modern life.

[Drug Name]

Generic name: Hepatitis A Vaccine (Human Diploid Cell), Inactivated

[Components and Description]

The inactivated hepatitis A vaccine is a preparation made from hepatitis A virus (HAV) LV8 strain grown in human diploid cell KMB17 strain. After cultivation and harvest, the virus suspension Is purified and inactivated. A quantity of aluminum adjuvant is added to make the vaccine.It is a slightly milky-white suspension. Stratified precipitate may form which can be dispersed by shaking.

Active constituent: Inactivated hepatitis A virus.

Excipients: Aluminum hydroxide,2-phenoxyethanol, glycine,sodium hydrogen sulfite, sodium hydroxide, and phosphate buffered saline(PBS).

[Eligibles]

Hepatitis A-susceptible individuals aged over 15 years old (excluding 15 years old).

[Strength]

1.0 ml per syringe, 1.0 ml per single human dose for adult, containing 640 EU of hepatitis A virus antigen.

[Administration and Dosage]

(1) Shake well before use. Inject single human dose IM at the deltoid insertion area of the lateral upper arm.

(2) Eligibles over 15 years old (excluding 15 years old) should be given the adult dose, with 1 dose of vaccine for initial immunization and 1 dose of vaccine for booster immunization at 6-month intervals. Each dose is 1.0 ml.

AIM Persistence Biopharmaceutical Co., Ltd. is the manufacturer of Meningococcal Vaccine and a reliable partner with strong R&D capabilities, making it a worthy long-term collaborator. Our vaccine provides protection against four types of infections with a single dose, effectively preventing complex infection scenarios and offering more comprehensive protection.

What is ACYW135 Meningococcal Polysaccharide Vaccine?

ACYW135 Meningococcal Polysaccharide Vaccine is a preventive biological product used to prevent epidemic cerebrospinal meningitis (referred to as "meningitis").

Its core function is to resist the invasion of Neisseria meningitidis of four serogroups A, C, Y, and W135, build a comprehensive immune protection barrier for susceptible groups, and reduce the incidence rate, severe cases and mortality of meningitis.

Hazards of Meningitis

Epidemic cerebrospinal meningitis is an acute respiratory infectious disease caused by Neisseria meningitidis, which is mainly transmitted directly through droplets such as coughing and sneezing, with patients and carriers as the source of infection.

The disease has an acute onset and rapid changes, which can lead to death within 24 hours after the onset in severe cases. Even if cured, some patients may leave sequelae such as brain damage, hearing loss and mental retardation, which are extremely harmful to human health, especially the growth and development of children and adolescents.

Core Product Information

AIM Persistence -  Xin'er Cong®

Ingredients and Properties This product is made from the culture fluid of Group A, C, Y, and W135 Neisseria meningitidis, and the capsule polysaccharide antigens are extracted and purified separately, mixed, and then freeze-dried with lactose as a stabilizer. It is a white fluffy substance, and after reconstituted with the provided diluent, it becomes a colorless and clear liquid.

Active ingredients: Each human dose of this vaccine contains 50pμg of polysaccharide from Group A, C, Y, and W135 capsules.

Excipients: Each human dose contains 10.0mg of lactose.

Vaccine diluent: Sterile and pyrogen-free PBS.

Vaccination Target

At present, it is only recommended for use in high-risk populations of children over 2 years old and adults in the following scope:

1. Those who travel to or live in high-risk areas, such as the African meningitis belt (epidemic areas of Group A, C, Y, and W135 Neisseria meningitidis).

2. Those who may come into contact with Group A, C, Y, and W135 Neisseria meningitidis from the air in laboratory or vaccine production work.

3. High-risk populations in areas where the national health administrative departments predict an outbreak of Group Y and W135 Neisseria meningitidis infection based on epidemiological investigations.

Packaging specifications

Advantages of Xin'er Cong®

Xinercong® is a core vaccine brand under AIM Persistence Biopharmaceutical Co., Ltd. Since the launch in China, our ACYW135 Meningococcal Polysaccharide Vaccine has become a trusted preferred brand in the market with strict quality control, advanced production technology.

The core advantages are reflected in the following aspects:

● Multiple serotypes: It can prevent meningococcal meningitis caused by the four dominant serogroups A, C, Y, and W135;

● High seroconversion rate: The seroconversion rates of antibodies in the four meningococcal serogroups A, C, Y, and W135 were all over 96%;

● Long validity period: The only meningococcal product with a validity period of 36 months;

● Low residue rate: No antibiotics or any preservatives are added during the production process.

Professional and modern production workshops are the cornerstone of high-quality products!

Marketing Authorization Holder/Manufacturer: AIM Persistence Biopharmaceutical Co., Ltd.

Registered Address/Production Address: No. 29 Zhuquan Road, Science and Technology Industrial Park, Ninghai County, Ningbo City, Zhejiang Province

Contact us: If you have any further needs or inquiries, please feel free to contact us via international@aimbio.com!